Shuttle Pharmaceuticals is expected to report a Q2 2026 loss of approximately $0.45 per share on $0.00 in revenue, with the current stock price of $3.76 trading without a formal professional analyst price target. The primary story for this report is the company’s drastic 95% reduction in research and development spending and its unconventional pivot into Dogecoin mining through a new subsidiary.
Investors are awaiting updates on the Phase 2 clinical trial of Ropidoxuridine for glioblastoma, which remains the core oncology asset despite the shift in corporate strategy. Management's guidance regarding cash runway and the sustainability of its pharmaceutical pipeline amidst mounting legal fees will be critical for assessing long-term shareholder value.